Tracer library / [212Pb]Pb-TCMC-chOI-1
[212Pb]Pb-TCMC-chOI-1
Also written as [Pb-212]Pb-TCMC-chOI-1; Pb-212-TCMC-chOI-1
- Radionuclide
- Pb-212 t½ 638.4 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 2
What it is
- Compound class
- Radiolabeled antibody (antibody-radionuclide conjugate) using TCMC chelator conjugated to chimeric anti-PTK7 IgG1 antibody (chOI-1)
- Target / mechanism
- Targets PTK7 (protein tyrosine kinase 7) expressed on tumor cells via chimeric anti-PTK7 antibody chOI-1, delivering alpha-emitting 212Pb PMID 40495114
- Clinical application
- PTK7-expressing ovarian cancer (intraperitoneal xenograft model) PMID 40495114
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | >96% | TCMC (p-SCN-Bn-TCMC) Macrocyclics | 40495114 2025 Mol Cancer Ther Antibodies mOI-1, chOI-1, and hIgG1 in carbonate buffer were conjugated with 5- to 20-fold molar excess of TCMC |
| Manual synthesis n/a | — | — | 85.9±4.7% | — | p-SCN-Bn-TCMC-PSMA (NG001) | 31919866 2020 J Labelled Comp Radiopharm Both ligands were efficiently labelled with 212 Pb using a 224 Ra/212 Pb-solution generator in transient equilibrium with progeny. - Lead-212-labelled NG001 was purified with a yield of 85.9±4.7% and with 0.7±0.2% of 224 Ra. |
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- Macrocyclics
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [212Pb]Pb-TCMC-chOI-1, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40495114: 'conjugated with 5- to 20-fold molar excess of TCMC (Macrocyclics Inc)'. Stage set/updated at stage 23 from PMID 40495114: 'Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy.'.